Go to the list of all blogs
Allana's Avatar
published in Blogs
May 17, 2019
TickeronGET DAILY SIGNALS
Five states to join lawsuit of OxyContin maker Purdue Pharma

Five states to join lawsuit of OxyContin maker Purdue Pharma

Five U.S. states filed lawsuits accusing Purdue Pharma of illegally marketing and selling opioids, escalating the wave of litigation over a nationwide abuse epidemic. Iowa, Kansas, Maryland, West Virginia and Wisconsin joined 39 states to file lawsuits targeting Purdue Pharma and its leaders, including former president Richard Sackler and his family. 

Officials accused Purdue Pharma of repeatedly making false and deceptive claims that opioids, including OxyContin, were safe for a wide range of patients seeking to reduce pain. 

Purdue Pharma called the new lawsuits “misleading attacks.” “These complaints are part of a continuing effort to try these cases in the court of public opinion rather than the justice system,” the Stamford, Connecticut-based company said.

Related Ticker: FTXH

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


FTXH's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for FTXH turned positive on October 15, 2026. Looking at past instances where FTXH's MACD turned positive, the stock continued to rise in 44 of 48 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on FTXH as a result. In 75 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

FTXH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FTXH crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +2.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in 252 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

FTXH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA).

Industry description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq U.S. Smart Pharmaceuticals TM Index. The fund will normally invest at least 80% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Market Cap

The average market capitalization across the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF is 77.49B. The market cap for tickers in the group ranges from 3.24B to 1.26T. LLY holds the highest valuation in this group at 1.26T. The lowest valued company is ELVN at 3.24B.

High and low price notable news

The average weekly price growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was 4%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 31%. ORKA experienced the highest price growth at 21%, while IOVA experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the First Trust Nasdaq Pharmaceuticals ETF (FTXH) ETF was 33%. For the same stocks of the ETF, the average monthly volume growth was 3% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 51
Price Growth Rating: 40
SMR Rating: 67
Profit Risk Rating: 56
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
FTXH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
120 East Liberty Drive, Suite 400Wheaton, Illinois 60187Wheaton
Phone
(800) 621-1675
Web
http://www.ftportfolios.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.